Close Menu

NEW YORK ─ Bio-Me and Siolta Therapeutics on Monday announced that they have entered into a collaboration and marketing agreement to develop a rapid diagnostic test for newborns at risk of developing allergy and asthma later in life.

Siolta will provide samples and insights into key criteria to Bio-Me as part of the deal.

The test would also help San Carlos, California-based Siolta identify and monitor patients eligible for its biotherapeutic therapy currently under development, the firms said.

Financial and other terms of the agreement were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The European Medicines Agency recommends that a warning about the possibility of blood clots be added to the product information.

According to Agence France Presse, astronauts who are to arrive soon at the International Space Station are to study the effect of microgravity on brain organoids and more.

A new study finds that farmed fish have led to a decline in genetic diversity among Atlantic salmon, the Guardian reports.

In Cell this week: analysis of SARS-CoV-2 B.1.1.7 introductions to the US, increased horizontal gene transfer higher in gut microbiomes linked to industrialization, and more.